Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Baxter Healthcare Corporation | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this analysis is to compare Hemoglobin and Hematocrit levels following total hip or knee arthroplasty. The utilization of FloSeal intraoperatively will improve hemostasis postoperatively. Decreasing bleeding time will decrease the drop in level of Hemoglobin and Hematocrit which usually occurs postoperatively.
Retrospective Analysis of charts on patients having undergone Total Hip or Total Knee Arthroplasty. During the patient's hospitalization, lab values of Hg and Hct will be recorded for further analysis. Preoperative levels will be also noted to establish baselines.
Primary Data interest will be Hemoglobin (Hgb) level documented during hospitalization along with Hematocrit (HCT) and Red Blood Cell (RBC) data also collected.
Secondary Data gathered will consist of the following:
patient Demographics
Component Profile
Length of Stay
Anesthesia used
Anesthesiologist
EBL
drain type
Amount of drainage fluid recorded at 12 hour increments until discharge
Amount of FloSeal used
Type of Arthroplasty
500 patients in Total
100 Historical Control Patients, knees - no FloSeal (retrospective)
100 Patients, knees - 5mL FloSeal (retrospective)
100 Patients, knees- 10mL FloSeal (prospective)
100 Historical Control patients, hips-no FloSeal (retrospective)
100 retrospective patients, hips-5mL of FloSeal (retrospective
Patients scheduled for Total Knee Arthroplasty will be asked if they wish to participate in the part of the study utilizing 10mL of FloSeal. These patient will be consented and the their data will be retrospectively gathered.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FloSeal - Knee - control | 100 Historical Control Patients, knees - no FloSeal (retrospective) | ||
| FloSeal - Knee - 5ml | 100 Patients, knees - 5mL FloSeal (retrospective) | ||
| FloSeal - Knee - 10ml | 100 Patients, knees- 10mL FloSeal (prospective) | ||
| FloSeal - Hip - Control | 100 Historical Control patients, hips-no FloSeal (retrospective) | ||
| FloSeal - Hip - 5ml | 100 retrospective patients, hips-5mL of FloSeal (retrospective) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All Dr. Velyvis's patients that have had a Total Knee or Total Hip after January 1, 2007
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Charles Z Cyr, BA | Contact | 760-766-1227 | ccyr@desertortho.com |
| Name | Affiliation | Role |
|---|---|---|
| John H. Velyvis,, MD | Desert Orthopedic Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Desert Orthopedic Center | Rancho Mirage | California | 92211 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided